Fixed-ratio combination of basal insulin and GLP-1 receptor agonists:mechanism and clinical trials progress
10.3969/j.issn.1006-6187.2024.01.015
- VernacularTitle:基础胰岛素/胰高糖素样肽1受体激动剂固定比例复方制剂的药物作用机制及临床研究进展
- Author:
Jianzhong XIAO
1
Author Information
1. 102218 清华大学附属北京清华长庚医院内分泌科
- Keywords:
Basal insulin;
GLP-1 receptor agonists;
Fixed-ratio combination;
Mechanism of action
- From:
Chinese Journal of Diabetes
2024;32(1):70-75
- CountryChina
- Language:Chinese
-
Abstract:
Type 2 diabetes mellitus(T2DM)is a progressive disease that has a complex pathophys-iology mechanism.As T2DM progresses,a combination of antidiabetic drugs with multiple mechanisms of action may often be required to correct the multiple pathophysiological defects to achieve glycemic control.The basal insulin/glucagon-like peptide-1 receptor agonist(GLP-1RA)fixed-ratio combination(FRC)is a once-daily injectable treatment that allows simultaneous administration of two antidiabetic drugs with complementary mechanisms,addressing seven of eight key defects in T2DM to achieve glycemic control comprehensively and effectively.This article will discuss the mechanism of action and clinical trials progress at home and abroad of basal insulin/GLP-1RA FRC,only to provide reference information for clinicians.
